Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11320%2F13%3A10144237" target="_blank" >RIV/00216208:11320/13:10144237 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/13:10144237 RIV/00064165:_____/13:10144237

Výsledek na webu

<a href="http://www.ecco-jccjournal.org/article/S1873-9946(12)00456-4/abstract" target="_blank" >http://www.ecco-jccjournal.org/article/S1873-9946(12)00456-4/abstract</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.crohns.2012.10.019" target="_blank" >10.1016/j.crohns.2012.10.019</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease

Popis výsledku v původním jazyce

Background and aims: Over 10% of Crohn's disease (CD) patients annually lose response to infliximab. Infliximab trough levels (TL), concomitant immunosuppressants and endoscopic healing were proposed as predictors of favourable infliximab outcome. We assessed infliximab TL measured after induction therapy as predictors of sustained clinical response. Furthermore, we tried to identify other predictors of long-term benefit of infliximab therapy. Methods: We included CD patients treated with infliximab between October 2007 and March 2010 who responded to 3-dose induction followed by maintenance therapy and in whom blood samples taken at treatment week 14 or 22 were available in blood bank. Sustained response to infliximab was defined as absence of treatment failure due to loss of response or drug intolerance. Results: Eighty four patients were included. Sustained response to infliximab was observed in 47 (56%) patients during a median follow-up of 25 months (14-37). lnfliximab TL>3 mu g/m

Název v anglickém jazyce

Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease

Popis výsledku anglicky

Background and aims: Over 10% of Crohn's disease (CD) patients annually lose response to infliximab. Infliximab trough levels (TL), concomitant immunosuppressants and endoscopic healing were proposed as predictors of favourable infliximab outcome. We assessed infliximab TL measured after induction therapy as predictors of sustained clinical response. Furthermore, we tried to identify other predictors of long-term benefit of infliximab therapy. Methods: We included CD patients treated with infliximab between October 2007 and March 2010 who responded to 3-dose induction followed by maintenance therapy and in whom blood samples taken at treatment week 14 or 22 were available in blood bank. Sustained response to infliximab was defined as absence of treatment failure due to loss of response or drug intolerance. Results: Eighty four patients were included. Sustained response to infliximab was observed in 47 (56%) patients during a median follow-up of 25 months (14-37). lnfliximab TL>3 mu g/m

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

BB - Aplikovaná statistika, operační výzkum

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Crohn's and Colitis

ISSN

1873-9946

e-ISSN

—

Svazek periodika

7

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

8

Strana od-do

736-743

Kód UT WoS článku

000323995900007

EID výsledku v databázi Scopus

—